NeuroSigma
Los Angeles, US · 1 known investors
NeuroSigma is a bioelectronic medical device company that makes non-invasive external trigeminal-nerve stimulation systems to treat chronic neurological and neuropsychiatric disorders. Its Monarch eTNS System is an FDA-cleared, prescription home-use device for treating pediatric ADHD in children ages 7 to 12, with additional programs targeting conditions such as autism spectrum disorder, epilepsy, and depression.</parameter> <parameter name="founders">[]
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$11.7M disclosed across 1 round · 2016
▶$11.7MraisedAug 2016 · 9 investors · Other Health CareRule 506(b)
- Leon EkchianExecutive Officer, Director
- Kirk CalhounDirector
- Lodwrick M. CookDirector
- James HindmanDirector
- Amount sold
- $11.7M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Companies competing with NeuroSigma for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $415.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2016 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $618.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $746.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $682.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does NeuroSigma do?
- NeuroSigma is a bioelectronic medical device company that makes non-invasive external trigeminal-nerve stimulation systems to treat chronic neurological and neuropsychiatric disorders. Its Monarch eTNS System is an FDA-cleared, prescription home-use device for treating pediatric ADHD in children ages 7 to 12, with additional programs targeting conditions such as autism spectrum disorder, epilepsy, and depression.</parameter> <parameter name="founders">[]
- Who founded NeuroSigma?
- NeuroSigma was founded by Leon Ekchian.
- Who are NeuroSigma's investors?
- NeuroSigma's investors include Checkmate Capital Group LLC.
- How much funding has NeuroSigma raised?
- NeuroSigma has disclosed $11.7M raised across 1 round.
- Where is NeuroSigma headquartered?
- NeuroSigma is headquartered in Los Angeles, US.